1. Inici
  2. Publicacions
  3. A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients

A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients

Data de publicació:

Autors de IIS La Fe

Autors aliens a IIS La Fe

  • Pineda, B
  • Diaz-Lagares, A
  • Perez-Fidalgo, JA
  • Burgues, O
  • Gonzalez-Barrallo, I
  • Crujeiras, AB
  • Esteller, M
  • Lluch, A
  • Eroles, P

Grups d'Investigació

Abstract

BackgroundPathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) varies between 30 and 40% approximately. To provide further insight into the prediction of pCR, we evaluated the role of an epigenetic methylation-based signature.MethodsEpigenetic assessment of DNA extracted from biopsy archived samples previous to NAC from TNBC patients was performed. Patients included were categorized according to previous response to NAC in responder (pCR or residual cancer burden, RCB=0) or non-responder (non-pCR or RCB>0) patients. A methyloma study was performed in a discovery cohort by the Infinium HumanMethylation450 BeadChip (450K array) from Illumina. The epigenetic silencing of those methylated genes in the discovery cohort were validated by bisulfite pyrosequencing (PyroMark Q96 System version 2.0.6, Qiagen) and qRT-PCR in an independent cohort of TN patients and in TN cell lines.ResultsTwenty-four and 30 patients were included in the discovery and validation cohorts, respectively. In the discovery cohort, nine genes were differentially methylated: six presented higher methylation in non-responder patients (LOC641519, LEF1, HOXA5, EVC2, TLX3, CDKL2) and three greater methylation in responder patients (FERD3L, CHL1, and TRIP10). After validation, a two-gene (FER3L and TRIP10) epigenetic score predicted RCB=0 with an area under the ROC curve (AUC)=0.905 (95% CI=0.805-1.000). Patients with a positive epigenetic two-gene score showed 78.6% RCB=0 versus only 10.7% RCB=0 if signature were negative.ConclusionsThese results suggest that pCR in TNBC could be accurately predicted with an epigenetic signature of FERD3L and TRIP10 genes. Further prospective validation of these findings is warranted.

Dades de la publicació

ISSN/ISSNe:
1868-7083, 1868-7075

Clinical epigenetics  BIOMED CENTRAL LTD

Tipus:
Article
Pàgines:
33-33
PubMed:
30786922
Factor d'Impacte:
2,005 SCImago ℠
Quartil:
Q1 SCImago ℠

Cites Rebudes en Web of Science: 35

Documents

  • No hi ha documents

Mètriques

Filiacions mostrar / ocultar

Keywords

  • Triple-negative breast cancer; Prediction; Epigenetic signature

Projectes associats

RED TEMATICA DE INVESTIGACION COOPERATIVA EN CANCER (RTICC)

Investigador Principal: MIGUEL ÁNGEL SANZ ALONSO

RD12/0036/0014 . INSTITUTO DE SALUD CARLOS III . 2013

INTEGRATIVE (EPI)GENOMIC AND DRUG TARGET ANALYSIS FOR IDENTIFICATION/VALIDATION OF CLINICALLY VALUABLE BIOMARKERS TO IMPROVE THE POOR OUTCOME OF NON-SMALL CELL LUNG CANCER PATIENTS.

Investigador Principal: JUAN SANDOVAL DEL AMOR

CP13/00055 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2015

ADQUISICIÓN DE UNA PLATAFORMA BIG DATA PARA EL ANÁLISIS Y LA GESTIÓN DE DATOS MULTI-ÓMICOS Y CLÍNICOS ORIENTADA A LA MEDICINA DE PRECISIÓN.

Investigador Principal: JOSÉ VICENTE CASTELL RIPOLL

FUFE15-EE-3906 . MINISTERIO DE ECONOMIA Y COMPETITIVIDAD . 2016

IMPLANTACIÓN DE LA MEDICINA PERSONALIZADA EN ONCOLOGÍA PEDIÁTRICA: FARMACOGENÉTICA, EPIGENÉTICA, METABOLÓMICA Y LOS SISTEMAS DE INFORMACIÓN.

Investigador Principal: MARÍA JOSÉ HERRERO CERVERA

MJH-CIS-2016-01 . FUNDACION MUTUA MADRILEÑA . 2016

VALIDACIÓN/IDENTIFICACIÓN DE BIOMARCADORES EPIGENÓMICOS PARA DIAGNOSTICO PRECOZ Y RESPUESTA A FÁRMACO PARA MEJORAR EL MALA EVOLUCIÓN DE PACIENTES CON CÁNCER DE PULMÓN CÉLULA NO PEQUEÑA.

Investigador Principal: JUAN SANDOVAL DEL AMOR

PI16/00295 . INSTITUTO DE SALUD CARLOS III . 2017

Validation/Identification of clinically valuable epigenomic biomarkers for early diagnosis to improve the current poor outcome of non-small cell lung cancer patients.

Investigador Principal: JUAN SANDOVAL DEL AMOR

2017_0367_CRC_GECP_SANDOVAL . FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2017

Compartir la publicació